Global Patent Index - EP 0555302 A1

EP 0555302 A1 19930818 - METHOD OF TREATING DEMYELINATING DISEASE.

Title (en)

METHOD OF TREATING DEMYELINATING DISEASE.

Title (de)

VERFAHREN ZUR BEHANDLUNG VON DIMYELINIERENDEN KRANKHEITEN.

Title (fr)

PROCEDE DE TRAITEMENT DES MALADIES DEMYELINISANTES.

Publication

EP 0555302 A1 19930818 (EN)

Application

EP 91918867 A 19911029

Priority

  • GB 9023600 A 19901030
  • GB 9023607 A 19901030

Abstract (en)

[origin: WO9207564A2] A calcium antagonist especially nimodipine, is used for the treatment of demyelinating diseases such as multiple sclerosis. It may be used in combination with an antiviral compound which is active against retroviruses, such as azidothymidine.

Abstract (fr)

Antagoniste calcique, notamment la nimodipine, servant au traitement des maladies démyélinisantes telles que la sclérose en plaques, et pouvant s'associer à un composé antiviral, par exemple l'azidothymidine, dont l'activité est dirigée contre les rétrovirus.

IPC 1-7

A61K 31/135; A61K 31/44; A61K 31/495; A61K 31/55; A61K 31/70

IPC 8 full level

A61K 31/275 (2006.01); A61K 31/135 (2006.01); A61K 31/44 (2006.01); A61K 31/495 (2006.01); A61K 31/505 (2006.01); A61K 31/55 (2006.01); A61K 31/70 (2006.01); A61P 25/00 (2006.01); A61P 31/12 (2006.01)

CPC (source: EP)

A61K 31/135 (2013.01); A61K 31/44 (2013.01); A61K 31/495 (2013.01); A61K 31/55 (2013.01); A61K 31/70 (2013.01); A61P 25/00 (2017.12); A61P 31/12 (2017.12)

C-Set (source: EP)

  1. A61K 31/70 + A61K 31/55
  2. A61K 31/70 + A61K 31/44
  3. A61K 31/70 + A61K 31/275
  4. A61K 31/70 + A61K 2300/00

Citation (search report)

  • [A] EP 0361831 A1 19900404 - WELLCOME FOUND [GB]
  • [A] WO 9101137 A1 19910207 - HARMENBERG JOHAN [SE], et al
  • [A] EP 0289229 A1 19881102 - WELLCOME FOUND [GB]
  • [A] K. YANAGISAWA ET AL.: "Degradation of myelin basic protein by calcium-activated neutral protease (CANP) in human brain and inhibition by E-64 analogue", NEUROCHEM. RES., VOL. 8, NO. 10, 1983, PLENUM PUBLISHING, pages 1285 - 1293, XP002091414
  • [A] H.A.N. EL-FAWAL ET AL.: "Effect of verapamil on organophosphorus-induced delayed neuropathy in hens", TOXICOL. APPL. PHARMACOL., VOL. 97, NO. 3, 1989, ACADEMIC PRESS, INC., pages 500 - 511, XP002091415
  • [A] J.H. WEISS ET AL.: "The calcium channel blocker nifedipine attenuates slow excitatory amino acid neurotoxicity", SCIENCE, VOL. 247, 23RD MARCH 1990, pages 321 - 330, XP002091416
  • [A] R.L. GILMORE ET AL.: "Verapamil-induced changes in central conduction in patients with multiple sclerosis", JOURNAL OF NEUROLOGY, NEUROSURGERY, AND PSYCHIATRY, VOL. 48, NO. 11, NOVEMBER 1985,, pages 1140 - 1146, XP002091417
  • See references of WO 9207564A2

Designated contracting state (EPC)

AT BE CH DE DK ES FR GB GR IT LI LU NL SE

DOCDB simple family (publication)

WO 9207564 A2 19920514; WO 9207564 A3 19920625; EP 0555302 A1 19930818; JP H06502155 A 19940310

DOCDB simple family (application)

GB 9101890 W 19911029; EP 91918867 A 19911029; JP 51713891 A 19911029